Related Experiment Video
Updated: Jul 28, 2025
08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.3K
Dapagliflozin in people with chronic kidney disease
Rochelle D Sylvester1, Teck K Khong2
1Clinical Pharmacology, St George's University of London, London, UK.
Drug and Therapeutics Bulletin
|May 31, 2023
Insights
Dapagliflozin significantly slowed chronic kidney disease progression in patients with and without diabetes. This sodium-glucose cotransporter-2 inhibitor demonstrated substantial renal benefits, offering a new treatment avenue.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Background:
- Chronic kidney disease (CKD) affects millions globally, leading to kidney failure.
- Current treatments for CKD primarily manage symptoms and slow progression.
- There is a need for therapies that target underlying disease mechanisms to preserve kidney function.
Purpose of the Study:
- To evaluate the efficacy of dapagliflozin in slowing the progression of CKD.
- To assess the impact of dapagliflozin on kidney and cardiovascular outcomes in patients with CKD.
Main Methods:
- A large-scale, randomized, placebo-controlled trial involving patients with CKD.
- Participants received dapagliflozin or a placebo, with outcomes monitored over time.
- Key endpoints included a composite of kidney function decline and cardiovascular events.
Main Results:
- Dapagliflozin significantly reduced the risk of CKD progression by 30% compared to placebo.
- The drug demonstrated a 30% reduction in the risk of cardiovascular death or heart failure hospitalization.
- Adverse events were generally similar between the dapagliflozin and placebo groups.
Conclusions:
- Dapagliflozin is effective in slowing the progression of chronic kidney disease.
- The sodium-glucose cotransporter-2 inhibitor offers significant cardiorenal protection.
- Dapagliflozin represents a major advancement in CKD management for a broad patient population.
Abstract:
Commentary on: Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436-46. Series Editor: Dr Teck Khong, DTB Associate Editor, Clinical Pharmacology, St George's, University of London, UK.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
01:28Chronic Kidney Disease III: Interprofessional Care
51
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
51
01:24Chronic Kidney Disease II: Clinical Manifestations
46
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
46
01:25Chronic Kidney Disease I: Introduction
48
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
48
01:11Renal Failure: Dose Adjustments
127
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
127
01:18Chronic Kidney Disease IV: Nursing Management
29
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
29